NGL Fine-Chem Limited operates as a leading manufacturer of veterinary and human health APIs, offering high-quality products in both domestic and international markets.

In Q2FY26, revenue from operations surged to ₹120.26 crores, marking a notable 28.64% year-over-year growth fueled by strong demand across various regions.

The company is executing aggressive expansion plans, including brownfield and greenfield projects in Tarapur, poised to enhance capacity for regulated market penetration.

Management optimistically noted the first U.S. FDA API registration, marking a significant step towards entering lucrative U.S. markets alongside existing European regulatory compliance.

Despite the upbeat demand, the company remains cautiously optimistic, maintaining vigilance over sustaining the upturn and associated risks pertaining to pricing pressures and market dynamics.